Clinical trials: Hyperparathyroidism; Secondary, Renal
Chronic Kidney Disease, End Stage Renal Disease
Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia
Patients with chronic kidney disease (CKD) and those with end-stage renal disease (ESRD) undergoing renal replacement therapies show elevated serum phosphate levels which predispose them to cardiovascular calcifications and high…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Hyperphosphatemia, Renal Osteodystrophy
- Trial name
- NCT00374712
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hyperparathyroidism, Secondary
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
This study is designed to assess the efficacy and safety of etelcalcetide (AMG 416) compared with placebo in the treatment of SHPT in CKD patients receiving hemodialysis.
- Trial name
- NCT01788046
- Testing
- Etelcalcetide
- Where
- 106 sites in United States, Australia and 13 more
- Volunteers
- 515 people
- Sponsor
- Amgen
Renal Osteodystrophy
Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD
The proposed 6 month pilot and feasibility randomized trial will evaluate LMMS as an anabolic stimulus to bone in 30 adults on maintenance hemodialysis.
- Trial name
- NCT00364234
- Testing
- Low magnitude mechanical stimuli
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Secondary Hyperparathyroidism
A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416
This was a multiple-dose, double-blind, randomized, placebo-controlled study. Chinese subjects residing in Mainland China with chronic kidney disease (CKD) receiving hemodialysis were randomized in a 3:1 ratio to receive 5 mg…
- Trial name
- NCT03283098
- Testing
- Etelcalcetide
- Where
- 5 sites in China
- Volunteers
- 33 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in…
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Trial name
- NCT03588884
- Testing
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- OPKO Health, Inc.
Secondary Hyperparathyroidism Due to Renal Causes
Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy
In this study, investigators measure patient's voice frequency, swallowing function, and O2 desaturation of the 6 mins walking test before surgery and 4 months after surgery, to find the increase of voice frequency, and…
- Trial name
- NCT04267965
- Testing
- parathyroidectomy plus bilateral thymectomy and autotransplantation
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- Chang Gung Memorial Hospital
Secondary Hyperparathyroidism, Chronic Kidney Disease
Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients
This is an open label, single center, randomized, active comparator controlled study, comparing the effects of vitamin D replacement using oral ergocalciferol versus paricalcitol on parathyroid hormone (PTH) levels in patients…
- Trial name
- NCT00958451
- Testing
- Paricalcitol, Ergocalciferol
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Salem Veterans Affairs Medical Center
Secondary Hyperparathyroidism, End-stage Kidney Disease
The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD
Patients with end-stage kidney disease (ESKD) have an increased risk of cardiovascular mortality. High parathyroid hormone (PTH) from secondary hyperparathyroidism leads to increased efflux of phosphate and calcium from bone…
- Trial name
- CaT50HD (NCT06398002)
- Testing
- Dialysate calcium 1.50 mmol/L
- Volunteers
- 48 people
- Sponsor
- Iain Bressendorff
Hyperparathyroidism
Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects
Subjects on Hemodialysis will be randomized to AMG 073 or placebo. The screening period is a maximum of 30 days followed by a 26-week treatment period.
- Trial name
- NCT00527267
- Testing
- AMG 073
- Volunteers
- 320 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic…
- Trial name
- NCT00463021
- Testing
- Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Hyperparathyroidism, Arterial Stiffness
Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism
Active parathyroid glands among renal dialysis patients contribute to calcified and hardened blood vessels. Such damage to the blood vessels, in turn, takes a significant toll in terms of cardiovascular disease.
- Trial name
- NCT01143987
- Testing
- Cinacalcet
- Where
- Hong Kong
- Volunteers
- 44 people
- Sponsor
- Chinese University of Hong Kong
Kidney Disease, Secondary Hyperparathyroidism
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary…
- Conditions
- Kidney Disease, Secondary Hyperparathyroidism, Chronic Kidney Disease
- Trial name
- NCT00132431
- Testing
- Sensipar
- Volunteers
- 300 people
- Sponsor
- Amgen
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease Mineral and Bone Disorder
The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density
The prevalence of chronic kidney disease (CKD) in the adult population is estimated to 10%. CKD increases risk of bone fractures, cardiovascular disease and death.
- Trial name
- REPAIR-CKD (NCT07171216)
- Testing
- Treat to target
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Herlev Hospital
Hyperparathyroidism, Secondary
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
The purpose of this study is to characterize the safety and tolerability of single rising doses of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism.
- Trial name
- NCT01134562
- Testing
- Etelcalcetide
- Where
- 5 sites in United States, Australia
- Volunteers
- 28 people
- Sponsor
- KAI Pharmaceuticals
Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function
REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial
This pilot randomized, open-label, outcome blinded clinical trial is to evaluate the preliminary effects of low-dose Colchicine (LoDoCo) on coronary artery calcification (CAC) progression in adults with chronic kidney disease…
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function, Vascular Calcification, Coronary Artery Calcification
- Trial name
- RESOLVE-CKD (NCT07654231)
- Testing
- Low-dose Colchicine at 0.5mg daily, Usual Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Kidney Disease-Mineral and Bone Disorder
To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease With MRI
Patients with chronic kidney disease (CKD) have a higher risk of fractures than those without. The purpose of this study is to develop a non-invasive Magnetic resonance imaging (MRI) method that can improve fracture risk…
- Trial name
- NCT04564924
- Testing
- DXA
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Chronic Kidney Disease, Secondary Hyperparathyroidism
Active Vitamin D Effect on Left Ventricular Hypertrophy
Left ventricular hypertrophy (LVH) predicts mortality at start of dialysis. Prevention of of LVH is important. It is not known whether secondary hyperparathyroidism might induce LVH.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Left Ventricular Hypertrophy
- Trial name
- NCT00175149
- Testing
- Alfacalcidiol
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Per Ivarsen
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
- Trial name
- NCT00037635
- Testing
- AMG 073
- Volunteers
- 400 people
- Sponsor
- Amgen
Hyperparathyroidism, Secondary
Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis
This study evaluates the metabolic and clinical results of two well recognized and accepted surgical techniques in the management of severe hyperparathyroidism in patients under regular dialysis treatment.
- Trial name
- NCT02464072
- Testing
- Subtotal Parathyroidectomy, Total Parathyroidectomy + 45 autografts, Total Parathyroidectomy + 90 autografts
- Where
- Brazil
- Volunteers
- 133 people
- Sponsor
- University of Sao Paulo General Hospital